Anthony Joetham1, Michaela Schedel1, Brian P O'Connor2, Soohyun Kim1, Katsuyuki Takeda1, Jordan Abbott1, Erwin W Gelfand3. 1. Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colo. 2. Center for Genes, Environment & Health, National Jewish Health, Denver, Colo. 3. Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colo. Electronic address: gelfande@njhealth.org.
Abstract
BACKGROUND: Regulatory T cells attenuate development of asthma in wild-type (WT) mice, with both naturally occurring regulatory T (nTreg) cells and inducible regulatory T (iTreg) cells exhibiting suppressive activity. When transferred into CD8-deficient (CD8-/-) recipients, both cell types enhanced development of allergen-induced airway hyperresponsiveness. OBJECTIVE: We sought to determine whether the pathways leading to enhancement of lung allergic responses by transferred nTreg and iTreg cells differed. METHODS: nTreg cells (CD4+CD25+) were isolated from WT mice and iTreg cells were generated from WT CD4+CD25- T cells after activation in the presence of TGF-β and transferred into sensitized CD8-/- recipients before challenge. Development of airway hyperresponsiveness, cytokine levels, and airway inflammation were monitored. RESULTS: Transfer of nTreg cells enhanced lung allergic responses, as did transfer of iTreg cells. Although anti-IL-13 reduced nTreg cell-mediated enhancement, it was ineffective in iTreg cell-mediated enhancement; conversely, anti-IL-17, but not anti-IL-13, attenuated the enhancement by iTreg cells. Recovered iTreg cells from the lungs of CD8-/- recipients were capable of IL-17 production and expressed high levels of signature genes of the TH17 pathway, RORγt and Il17, whereas reduced expression of the Treg cell key transcription factor forkhead box p3 (Foxp3) was observed. In vitro exogenous IL-6-induced IL-17 production in iTreg cells, and in vivo conversion of transferred iTreg cells was dependent on recipient IL-6. CONCLUSIONS: iTreg cells, similar to nTreg cells, exhibit functional plasticity and can be converted from suppressor cells to pathogenic effector cells, enhancing lung allergic responses, but these effects were mediated through different pathways.
BACKGROUND: Regulatory T cells attenuate development of asthma in wild-type (WT) mice, with both naturally occurring regulatory T (nTreg) cells and inducible regulatory T (iTreg) cells exhibiting suppressive activity. When transferred into CD8-deficient (CD8-/-) recipients, both cell types enhanced development of allergen-induced airway hyperresponsiveness. OBJECTIVE: We sought to determine whether the pathways leading to enhancement of lung allergic responses by transferred nTreg and iTreg cells differed. METHODS: nTreg cells (CD4+CD25+) were isolated from WT mice and iTreg cells were generated from WT CD4+CD25- T cells after activation in the presence of TGF-β and transferred into sensitized CD8-/- recipients before challenge. Development of airway hyperresponsiveness, cytokine levels, and airway inflammation were monitored. RESULTS: Transfer of nTreg cells enhanced lung allergic responses, as did transfer of iTreg cells. Although anti-IL-13 reduced nTreg cell-mediated enhancement, it was ineffective in iTreg cell-mediated enhancement; conversely, anti-IL-17, but not anti-IL-13, attenuated the enhancement by iTreg cells. Recovered iTreg cells from the lungs of CD8-/- recipients were capable of IL-17 production and expressed high levels of signature genes of the TH17 pathway, RORγt and Il17, whereas reduced expression of the Treg cell key transcription factor forkhead box p3 (Foxp3) was observed. In vitro exogenous IL-6-induced IL-17 production in iTreg cells, and in vivo conversion of transferred iTreg cells was dependent on recipient IL-6. CONCLUSIONS: iTreg cells, similar to nTreg cells, exhibit functional plasticity and can be converted from suppressor cells to pathogenic effector cells, enhancing lung allergic responses, but these effects were mediated through different pathways.
Authors: Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu Journal: Nat Med Date: 2002-07-29 Impact factor: 53.440
Authors: Aysefa Doganci; Tatjana Eigenbrod; Norbert Krug; George T De Sanctis; Michael Hausding; Veit J Erpenbeck; El-Bdaoui Haddad; Hans A Lehr; Edgar Schmitt; Tobias Bopp; Karl-J Kallen; Udo Herz; Steffen Schmitt; Cornelia Luft; Olaf Hecht; Jens M Hohlfeld; Hiroaki Ito; Norihiro Nishimoto; Kazuyuki Yoshizaki; Tadamitsu Kishimoto; Stefan Rose-John; Harald Renz; Markus F Neurath; Peter R Galle; Susetta Finotto Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: Rhonda H Wilson; Gregory S Whitehead; Hideki Nakano; Meghan E Free; Jay K Kolls; Donald N Cook Journal: Am J Respir Crit Care Med Date: 2009-08-06 Impact factor: 21.405
Authors: Katrin Presser; Dorothee Schwinge; Michael Wegmann; Samuel Huber; Steffen Schmitt; Alexander Quaas; Joachim H Maxeiner; Susetta Finotto; Ansgar W Lohse; Manfred Blessing; Christoph Schramm Journal: J Immunol Date: 2008-12-01 Impact factor: 5.422
Authors: Rajatava Basu; Sarah K Whitley; Suniti Bhaumik; Carlene L Zindl; Trenton R Schoeb; Etty N Benveniste; Warren S Pear; Robin D Hatton; Casey T Weaver Journal: Nat Immunol Date: 2015-02-02 Impact factor: 25.606
Authors: Mingjing Hu; Bilal Alashkar Alhamwe; Brigitte Santner-Nanan; Sarah Miethe; Hani Harb; Harald Renz; Daniel P Potaczek; Ralph K Nanan Journal: Int J Mol Sci Date: 2022-05-20 Impact factor: 6.208